Table 5. BRMS1 promoter methylation in cell-free DNA circulating in plasma of patients with advanced NSCLC cancer (n=74): univariate and multivariate analysis for PFS and OS.

	Univariate analysisa			Multivariate analysisa
	Hazard ratio	95% CI	P	Hazard ratio	95% CI	P
Progression-free survival (PFS)
Sex (male vs female)	1.141	0.584–2.233	0.699
Age (⩾ 65 vs <65)	1.122	0.706–1.784	0.626
Age (<70 vs ⩾70)	1.052	0.632–1.751	0.845
Performance status (2 vs 0-1)	1.548	0.826–2.904	0.173
Histology (non-squamous vs squamous)	1.391	0.834–2.320	0.206
Regimen (non-plat. vs plat.)	1.328	0.776–2.273	0.302
BRMS1 promoter methylation (yes vs no)	1.945	1.174–3.223	0.010	1.951	1.175–3.238	0.010
Overall survival
Sex (male vs female)	1.532	0.754–3.112	0.238
Age (⩾ 65 vs <65)	1.012	0.632–1.624	0.959
Age (<70 vs ⩾70)	1.060	0.625–1.800	0.828
Performance status (2 vs 0-1)	1.924	1.027–3.606	0.041	1.861	0.989–3.500	0.054
Histology (non-squamous vs squamous)	1.282	0.780–2.107	0.327
Regimen (non-plat. vs plat.)	1.037	0.605–1.776	0.896
BRMS1 promoter methylation (yes vs no)	2.061	1.255–3.384	0.004	2.057	1.247–3.386	0.005

Abbreviations: BRMS1=breast-cancer metastasis suppressor 1; CI=confidence interval; NSCLC=non-small cell lung cancer; OS=overall survival. Statistically significant findings are shown in bold.

^aCox regression analysis.